Vikki Cerniglia
Senior Director - BioPharma Business Development Natera
Seminars
Tuesday 13th October 2026
From Residual Disease to Earlier Approval: Leveraging Molecular Residual Disease & ctDNA to Accelerate ADC Development
11:30 am
- Contextualizing how traditional endpoints in early-stage settings take many years to mature, which makes ADC development slow and expensive
- Exploring MRD as a potential shortcut by showing that an ADC converts patients from MRD-positive to negative to get earlier signals and potentially approvals
- Providing customized real-world data analyses to help benchmark ADC treatment outcomes and disease progression kinetics, and incorporating ctDNA-guided development and molecular response analysis to support ADCs clinical development
